Journal article
Shared activity patterns arising at genetic susceptibility loci reveal underlying genomic and cellular architecture of human disease
J Kenneth Baillie, Andrew Bretherick, Christopher S Haley, Sara Clohisey, Alan Grays, Lucile PA Neyton, Jeffrey Barrett, Eli A Stahl, Albert Tenesa, Robin Andersson, J Ben Brown, Geoffrey J Faulkner, Marina Lizio, Ulf Schaefer, Carsten Daub, Masayoshi Itoh, Naoto Kondo, Timo Lassmann, Jun Kawai, Damian Mole Show all
PLOS COMPUTATIONAL BIOLOGY | PUBLIC LIBRARY SCIENCE | Published : 2018
Related Projects (2)
Grants
Awarded by Wellcome Trust
Awarded by Wellcome-Beit Prize
Awarded by BBSRC Institute Strategic Programme
Awarded by BBSRC
Awarded by NHMRC
Awarded by EU
Awarded by European Research Council (ERC) under the European Unions
Awarded by ERC
Awarded by Australian National Health and Medical Research council
Awarded by Australian Red Cross
Awarded by Biotechnology and Biological Sciences Research Council
Awarded by Medical Research Council
Awarded by NATIONAL HUMAN GENOME RESEARCH INSTITUTE
Funding Acknowledgements
JKB gratefully acknowledges funding support from a Wellcome Trust Intermediate Clinical Fellowship (103258/Z/13/Z) and a Wellcome-Beit Prize (103258/Z/13/A), BBSRC Institute Strategic Programme Grants to the Roslin Institute (BBS/E/D/20211551, BBS/E/D/20211552, BBS/E/D/20211553, BBS/E/D/20231760), the UK Intensive Care Foundation, and the Edinburgh Clinical Academic Track (ECAT) scheme. Funds were provided to the Roslin Institute through a BBSRC Strategic Programme Grant (JKB, SC, CSH, GJF, TCF, DAH; BBS/E/D/20211551, BBS/E/D/20231760). We acknowledge the financial support provided by the MRC-HGU Core Fund (CSH, AT). FANTOM5 was made possible by a Research Grant for RIKEN Omics Science Center from MEXT to YH and a Grant of the Innovative Cell Biology by Innovative Technology (Cell Innovation Program) from the MEXT, Japan to YH. RIKEN Centre for Life Science Technologies, Division of Genomic Technologies members (RIKEN CLST (DGT)) are supported by institutional funds from the MEXT, Japan. RIKEN Preventive Medicine and Diagnosis Innovation Program members are supported by funding from MEXT, Japan. ARRF is supported by a Senior Cancer Research Fellowship from the Cancer Research Trust and funds raised by the Ride to Conquer Cancer. JB is supported by Wellcome Trust grant WT098051. GJF acknowledges the support of an NHMRC Career Development Fellowship (GNT1045237), NHMRC Project Grants (GNT1042449, GNT1045991, GNT1067983 and GNT1068789), and the EU FP7 under grant agreement No. 259743 underpinning the MODHEP consortium. MR was supported by grants from the Deutsch Forschungsgemeinschaft, the German Cancer Aid and the Rudolf Bartling Foundation. RA was supported by funding from the European Research Council (ERC) under the European Unions Horizon 2020 research and innovation programme (grant agreement No 638273). US and VBB are supported by the KAUST Base Research Fund to VBB and KAUST CBRC Base Fund. RA and AS were supported by funds from FP7/2007-2013/ERC grant agreement 204135, the Novo Nordisk foundation, and the Lundbeck Foundation and the Danish Cancer Society. CAW is supported by a Queensland Government Smart Futures Fellowship, and samples were collected under Australian National Health and Medical Research council project grants 455947 and 597452, under agreement from the Australian Red Cross 11-02QLD-10 and the University of QLD ethics committee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.